Work

Molecular Imaging of Pulmonary Fibrosis

Year: 2025

Type: article

Abstract: Fibrosing lung diseases affect over 160,000 individuals in the United States alone and can carry a prognosis that is worse than many cancers. Antifibrotic treatments modify only the rate of fibrosis progression, and more effective therapies are urgently needed. Molecular imaging enables visualization of disease pathogenesis in progress. It provides a noninvasive means to monitor and quantify dysregulated molecular fibrotic pathways and shows great promise in aiding the diagnosis and disease activity monitoring of pulmonary fibrosis. Here, we review molecular imaging probes under development for use in pulmonary fibrosis. We provide our opinion on current challenges in translating preclinical molecular imaging probes into clinical successes, as well as future directions for expanding their use in drug development.

Source: Journal of Nuclear Medicine

DOI: 10.2967/jnumed.124.267852

Authors: Margaret B. Allison, Ciprian Catana, Iris Y. Zhou, Peter Caravan, Sydney B. Montesi

Institutions: Harvard University, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging

Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Heart, Lung, and Blood Institute